Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms

European Journal of Endocrinology · Published 2026-07-25 · DOI 10.1093/ejendo/lvag135

Free full text

Authors (4)

Lakshmipriya Thandiyekkal Rajan, Johannes Hofland, Eskeatnaf Mulugeta, Wouter W de Herder

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Rajan, L., Hofland, J., Mulugeta, E., et al. (2026). Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvag135

Related articles

• Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies · Endocrine Oncology · 2025 · Cites or is cited by this article
• Mid-pregnancy serum chemerin levels predict persistence of postpartum hypertension in patients with polycystic ovary syndrome · European Journal of Endocrinology · 2026 · Same journal
• Integrated Clinical–Genetic–Pathological Analysis Expands the Phenotypic and Molecular Spectrum of PPNAD Across Carney Complex and Isolated Forms · European Journal of Endocrinology · 2026 · Same journal
• Changes in serum TSH across the adult lifespan: 22-year follow-up of the HUNT Study · European Journal of Endocrinology · 2026 · Same journal
• Independent clonal evolution in primary pigmented nodular adrenocortical disease: a single-patient multi-omics study · European Journal of Endocrinology · 2026 · Same journal
• Baseline biochemical evaluation for etiologic differentiation in ACTH-dependent Cushing’s syndrome: machine learning and composite score analysis in a multicenter cohort of 566 patients. · European Journal of Endocrinology · 2026 · Same journal
• From concept to protocol: iterative approach of a target trial emulation on GnRH analog safety in transgender and gender diverse youth · European Journal of Endocrinology · 2026 · Same journal
• Magnesium as an endocrine modulator: physiological roles, clinical evidence, and therapeutic perspectives · European Journal of Endocrinology · 2026 · Same journal
• Continuous subcutaneous recombinant PTH(1-34) infusion improves serum calcium and phosphate homeostasis in children with autosomal dominant hypocalcemia type 1 refractory to standard-of-care treatment · European Journal of Endocrinology · 2026 · Same journal
• Targeted proteomics reveals novel biomarkers of disease activity and inflammation in acromegaly · European Journal of Endocrinology · 2026 · Same journal